Modeling neurogenesis impairment in down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells

Experimental Cell Research

Volumn 319, Issue 4, 2013, Pages 498-505

  Lu, Huai En ^a,b   Yang, Yao Chen ^a   Chen, Sheng Mei ^c   Su, Hong Lin ^c   Huang, Pai Cheng ^d   Tsai, Ming Song ^e,f   Wang, Tzu Hao ^d   Tseng, Ching Ping ^b   Hwang, Shiaw Min ^a  

^a FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Down syndrome; Induced pluripotent stem cells; MiRNA; Neurogenesis impairment; Trisomy 21

Indexed keywords

ALKALINE PHOSPHATASE; AMYLOID PRECURSOR PROTEIN; METHYL CPG BINDING PROTEIN 2; MICRORNA; MICRORNA 155; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ALZHEIMER DISEASE; AMNIOTIC FLUID CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CHROMOSOME 21; DOWN SYNDROME; EMBRYO; EMBRYOID BODY; FEEDER CELL; FETUS; GERM LAYER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; KARYOTYPING; MALE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECOND TRIMESTER PREGNANCY; SEVERE COMBINED IMMUNODEFICIENCY; TERATOMA; TRISOMY 21; AMNION FLUID; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; EVALUATION; FEMALE; GENETICS; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; THEORETICAL MODEL;

IPS;

AMNIOTIC FLUID; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DOWN SYNDROME; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, THEORETICAL; NEUROGENESIS; NEURONS; PREGNANCY;

MLCS; MLOWN;

EID: 84875543263     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.09.017     Document Type: Article

References (25)

1. Scott B.S., Becker L.E., Petit T.L. Neurobiology of Down's syndrome. Prog. Neurobiol. 1983, 21:199-237.
2. Coyle J.T., Oster-Granite M.L., Gearhart J.D. The neurobiologic consequences of Down syndrome. Brain. Res. Bull. 1986, 16:773-787.
3. Davisson M.T., Schmidt C., Reeves R.H., Irving N.G., Akeson E.C., Harris B.S., Bronson R.T. Segmental trisomy as a mouse model for Down syndrome. Prog. Clin. Biol. Res. 1993, 384:117-133.
4. Gardiner K., Costa A.C. The proteins of human chromosome 21. Am. J. Med. Genet. C Semin. Med. Genet. 2006, 142C:196-205.
5. Marchetto M.C., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., Chen G., Gage F.H., Muotri A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
6. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkela E., Hyttinen J., Kontula K., Swan H., Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setala K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2011.
7. Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H., Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011, 20:4530-4539.
8. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
9. Gunaseeli I., Doss M.X., Antzelevitch C., Hescheler J., Sachinidis A. Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr. Med. Chem. 2010, 17:759-766.
10. Jang J., Yoo J.E., Lee J.A., Lee D.R., Kim J.Y., Huh Y.J., Kim D.S., Hwang D.Y., Kim H.S., Kang H.C., Kim D.W. Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp Mol Med. 2011.
11. Ito D., Okano H., Suzuki N. Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann. Neurol. 2012, 72:167-174.
12. Becker L., Mito T., Takashima S., Onodera K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 1991, 373:133-152.
13. Kuhn D.E., Nuovo G.J., Terry A.V., Martin M.M., Malana G.E., Sansom S.E., Pleister A.P., Beck W.D., Head E., Feldman D.S., Elton T.S. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J. Biol. Chem. 2010, 285:1529-1543.
14. Kuhn D.E., Nuovo G.J., Martin M.M., Malana G.E., Pleister A.P., Jiang J., Schmittgen T.D., Terry A.V., Gardiner K., Head E., Feldman D.S., Elton T.S. Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem. Biophys. Res. Commun. 2008, 370:473-477.
15. Tsai M.S., Hwang S.M., Chen K.D., Lee Y.S., Hsu L.W., Chang Y.J., Wang C.N., Peng H.H., Chang Y.L., Chao A.S., Chang S.D., Lee K.D., Wang T.H., Wang H.S., Soong Y.K. Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem. Cells 2007, 25:2511-2523.
16. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
17. Kim B.K., Kim S.E., Shim J.H., Woo D.H., Gil J.E., Kim S.K., Kim J.H. Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells. FEBS Lett. 2006, 580:5869-5874.
18. Tsai M.S., Lee J.L., Chang Y.J., Hwang S.M. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod. 2004, 19:1450-1456.
19. De Coppi P., Bartsch G., Siddiqui M.M., Xu T., Santos C.C., Perin L., Mostoslavsky G., Serre A.C., Snyder E.Y., Yoo J.J., Furth M.E., Soker S., Atala A. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 2007, 25:100-106.
20. Li C., Zhou J., Shi G., Ma Y., Yang Y., Gu J., Yu H., Jin S., Wei Z., Chen F., Jin Y. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum. Mol. Genet. 2009, 18:4340-4349.
21. Koch C.M., Suschek C.V., Lin Q., Bork S., Goergens M., Joussen S., Pallua N., Ho A.D., Zenke M., Wagner W. Specific age-associated DNA methylation changes in human dermal fibroblasts. PLoS. One 2011, 6:e16679.
22. Banito A., Rashid S.T., Acosta J.C., Li S., Pereira C.F., Geti I., Pinho S., Silva J.C., Azuara V., Walsh M., Vallier L., Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes. Dev. 2009, 23:2134-2139.
23. Galende E., Karakikes I., Edelmann L., Desnick R.J., Kerenyi T., Khoueiry G., Lafferty J., McGinn J.T., Brodman M., Fuster V., Hajjar R.J., Polgar K. Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell. Reprogram. 2010, 12:117-125.
24. Shi Y., Kirwan P., Smith J., MacLean G., Orkin S.H., Livesey F.J. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 2012, 4:124ra129.
25. Porayette P., Gallego M.J., Kaltcheva M.M., Bowen R.L., Vadakkadath Meethal S., Atwood C.S. Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J. Biol. Chem. 2009, 284:23806-23817.